Rhumbline Advisers Grows Position in Sangamo Therapeutics, Inc. (SGMO)
Rhumbline Advisers increased its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 7.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 88,816 shares of the biopharmaceutical company’s stock after purchasing an additional 6,125 shares during the period. Rhumbline Advisers owned approximately 0.11% of Sangamo Therapeutics worth $1,332,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Sangamo Therapeutics by 12.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock worth $30,551,000 after purchasing an additional 384,031 shares during the last quarter. State Street Corp lifted its holdings in Sangamo Therapeutics by 51.6% during the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after purchasing an additional 636,296 shares during the last quarter. RA Capital Management LLC acquired a new stake in Sangamo Therapeutics during the 2nd quarter worth approximately $11,000,000. Northern Trust Corp lifted its holdings in Sangamo Therapeutics by 4.9% during the 2nd quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock worth $8,341,000 after purchasing an additional 44,656 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Sangamo Therapeutics by 3.1% during the 1st quarter. Geode Capital Management LLC now owns 633,964 shares of the biopharmaceutical company’s stock worth $3,296,000 after purchasing an additional 19,331 shares during the last quarter. 64.35% of the stock is owned by institutional investors and hedge funds.
In other news, Director Saira Ramasastry sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the transaction, the director now owns 5,000 shares in the company, valued at approximately $73,350. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William R. Ringo sold 31,000 shares of Sangamo Therapeutics stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $14.37, for a total value of $445,470.00. Following the completion of the transaction, the director now owns 31,800 shares in the company, valued at approximately $456,966. The disclosure for this sale can be found here. Insiders sold a total of 84,433 shares of company stock valued at $1,309,466 over the last ninety days. Insiders own 5.50% of the company’s stock.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) opened at $16.50 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64. Sangamo Therapeutics, Inc. has a fifty-two week low of $2.85 and a fifty-two week high of $18.40.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company’s quarterly revenue was up 333.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.27) EPS. research analysts anticipate that Sangamo Therapeutics, Inc. will post -0.73 EPS for the current fiscal year.
Several analysts recently weighed in on the company. Wells Fargo & Company reissued an “outperform” rating and set a $30.00 price target (up from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. Jefferies Group reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Sangamo Therapeutics in a report on Friday, October 13th. Piper Jaffray Companies raised Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price objective for the company in a report on Wednesday, November 15th. Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, November 15th. Finally, Barclays initiated coverage on Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Sangamo Therapeutics has a consensus rating of “Buy” and an average target price of $17.83.
ILLEGAL ACTIVITY NOTICE: “Rhumbline Advisers Grows Position in Sangamo Therapeutics, Inc. (SGMO)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/rhumbline-advisers-grows-position-in-sangamo-therapeutics-inc-sgmo/1762940.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.